This is an updated version of the original Cochrane Review published in 2015, Issue 4.
Objectives : To assess the efficacy and safety of baclofen for people with severe alcohol withdrawal syndrome. We included all randomised controlled clinical trials (RCTs) evaluating baclofen versus placebo or any other treatment for people with AWS. We excluded uncontrolled, non-randomised, or quasi-randomised trials.
Key results : We are uncertain whether baclofen improves withdrawal symptoms and signs and reduces side effects when compared with placebo or other medicines as the quality of the evidence was very low.
NB : les données des essais cliniques français Alpadir et Bacloville ne sont pas intégrées dans cette revue de la littérature. Les chercheurs ont retenu 3 essais cliniques randomisés menées auprès de 141 patients.
Jia Liu, Lu-Ning Wang, Cochrane Database of Systematic Reviews 2017, Issue 8